AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02583672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Description: 1800mg NAC twice daily (3600mg/day) orally for approximately 90 days.
Study NCT02152436 — intervention group
Intervention type: OTHER
Intervention: Simulation - based curriculum
Description: Operating room medical and non-medical members will be asked to carry out a simulation session preceded by an educational maze with videos. Outcomes will be compared and correlated after and before this curriculum
Study NCT04913870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Angiotensin Receptor Blockers
Description: Angiotensin Receptor Blockers treatment for 2 years.
Study NCT04913870 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administration for 2 years.
Study NCT04267562 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Minitouch System
Description: The investigational treatment (endometrial ablation) will be performed utilizing the Minitouch System
Study NCT02172651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Take five 10,000 IU capsules (total 50,000 IU) once daily for 7 days, followed by one 10,000 IU capsule once daily until surgery.
Study NCT02172651 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Take five placebo capsules once daily for 7 days, followed by one placebo capsule once daily until surgery.
Study NCT02344355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: oral temozolomide (75 mg/m2), given 7 days per week, for a maximum of 49 days during radiation therapy.~Starting 1 month after radiation therapy, additional temozolomide will be given as chemotherapy cycles. Each cycle is 28 days.~For the first cycle, temozolomide will be administered (150 mg/m2) once per day for 5 days.~If the subject tolerates the first cycle well, temozolomide will be prescribed at 200 mg/m2 for cycles 2 through 6. Each cycle is 28 days.
Study NCT02344355 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Conformal radiation administered daily, M-F, to a total dose of 61.2 Gray in 34 fractions.
Study NCT02344355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbic Acid
Description: Intravenous infusions of 87.5g of ascorbate administered three times weekly during radiation.~After radiation, ascorbate is administered twice weekly through the end of cycle 6 of temozolomide.
Study NCT05347797 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: therascreen® KRAS RGQ PCR Kit
Description: To utilize a Clinical Study assay, the therascreen® KRAS RGQ PCR Kit, as a screening test in Phase 3 of Clinical Study (Protocol No. 20190009), in order to identify patients with NSCLC with KRAS G12C mutation positive tumours.
Study NCT02998164 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: augmentative and alternative communication technology
Study NCT02998164 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: No change to the therapy care received
Study NCT01861301 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01861301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tivantinib
Description: Given PO
Study NCT03820258 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF/VEL/VOX
Description: Administered once daily with food.
Study NCT02891954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Description: Healthy volunteers will receive canagliflozin (300 mg per day) in the morning for five days.
Study NCT03141164 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: computerized training
Description: Computerized training
Study NCT03141164 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: computerized training
Description: Computerized training
Study NCT01589835 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle changes
Description: Green prescription with support from facilitator
Study NCT01589835 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Lifestyle changes
Description: Green prescription with support from facilitator
Study NCT01685008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MOR00208 (formerly Xmab 5574)
Study NCT01711801 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single ascending dose
Study NCT01711801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5545965
Description: Single ascending dose
Study NCT01711801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5545965
Description: Single dose, in fed and fasted state
Study NCT04626479 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Administered via IV infusion at a dose of 400 mg Q6W
Study NCT04626479 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Favezelimab/Pembrolizumab
Description: Administered via IV infusion at a dose of 800 mg/200 mg Q3W
Study NCT04626479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belzutifan
Description: Administered via oral tablet at a dose of 120 mg QD
Study NCT04626479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Administered via oral capsule at a dose of 20 mg QD
Study NCT04626479 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab/Quavonlimab
Description: Administered via IV infusion at a dose of 400 mg/25 mg Q6W
Study NCT04626479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vibostolimab/Pembrolizumab
Description: Administered via IV infusion at a dose of 200 mg/200 mg Q6W
Study NCT03258593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab 1500 mg is administered intravenously (IV) once every 4 weeks for 12 months with an option to continue therapy for an additional 12 months (total of 24 months) provided that, participant is tolerating therapy and remains free of recurrent high grade NMIBC (see Treatment Period below). The dose of durvalumab is 1500 mg. If optional maintenance therapy continued in the second year, durvalumab 1500 mg will be administered intravenously once every 3 months to provide an immune boost.
Study NCT01783522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glutamine
Description: Dose of 15 grams twice times daily (to equal 30 grams a day) for a period of 4 months.
Study NCT01783522 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study NCT01783522 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: quality-of-life assessment
Description: Ancillary studies
Study NCT01783522 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given PO
Study NCT03187951 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Participants complete 4 questionnaires about physical abilities, motivation, and quality of life They should take about 25 minutes total to complete.
Study NCT03187951 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutritional Questionnaire and Nutritional Counseling
Description: Participants complete a nutritional questionnaire and receive nutritional counseling. It should take about 5 minutes to complete. Participants receive educational materials and personalized counseling based on participant's answers.
Study NCT00011193 — intervention group
Intervention type: BEHAVIORAL
Intervention: Exercise
Description: Compared the effect of 50%, 100%, and 150% of the NIH Consensus Development Panel recommended physical activity dose on fitness in women.
Study NCT03258593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vicineum
Description: Vicineum is administered in a 12-week Induction Phase followed by a Maintenance Phase for at least one year with an option for a total of up to 2 years of treatment. During the Induction Phase, Vicineum is administered once weekly for 12 weeks. During the Maintenance Phase, Vicineum is administered every other week. The dose of Vicineum is 30 mg in 50 mL of saline.
Study NCT01893840 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FlowOx
Description: Boot-shaped pressure chamber generating pulsating negative pressure
Study NCT03187951 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Booklet
Description: Participants receive a booklet that contains a stretching guide with full-body stretches and safety.
Study NCT03187951 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise and Strength Training Exercises
Description: Participants complete up to 30 minutes of moderate-intensity aerobic exercise (such as brisk walking, stationary cycling, and/or elliptical or stair stepping machines) for at least 5 days each week. Participants complete strength training exercises at least 2 times per week.
Study NCT03187951 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phone Calls
Description: Participants contacted by phone by member of study staff one (1) time each week for the first 4 weeks, and then every 2 weeks after that for behavioral skills training and to see how participant is doing. These calls should last about 15 minutes.
Study NCT03258593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Acetaminophen or equivalent medications per institutional standard may be administered at the discretion of the investigator.
Study NCT03258593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antihistamine
Description: Antihistamine (e.g., diphenhydramine) or equivalent medications per institutional standard may be administered at the discretion of the investigator.
Study NCT01429246 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Regular Salt
Description: Estimated Household Individual Consumption of 30 grams per day
Study NCT01429246 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Salt Substitute
Description: Estimated 30 grams per day per household member
Study NCT03258593 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bladder Biopsy
Description: Bladder biopsy at screening and every 3 months before each cystoscopy per schema.
Study NCT03258593 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TURBT
Description: Transurethral resection of a bladder tumor (TURBT) at screening and every 3 months before each cystoscopy per schema.
Study NCT03258593 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cystoscopy
Description: Urine cytology at screening and every 3 months before each cystoscopy per schema.
Study NCT03258593 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Urine cytology
Description: Urine cytology at baseline and every 3 months before each cystoscopy per schema.
Study NCT03258593 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Electrocardiogram
Description: Electrocardiogram (ECG) at screening, pre-durvalumb infusion and as clinically indicated during the trial.
Study NCT03971695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 706321
Description: Capsule or Oral Solution
Study NCT03971695 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule or Oral solution
Study NCT03905811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terazosin 5 MG
Description: 5 milligrams by mouth daily at bedtime
Study NCT03905811 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: 1 capsule by mouth daily at bedtime
Study NCT02213679 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Guanidinoacetic acid
Description: Dietary supplement
Study NCT02213679 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04485780 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: botulinum toxin type A
Description: In the outpatient department, patients who need hemorrhoidectomy were randomly assigned to two groups at a 1:1 ratio using a computer-generated list of random numbers (Microsoft Excel). One group received Botulinum toxin injection during the outpatient clinic one week before the operation(experimental group, EG), and the other group received injection during the operation(control group, CG). The two groups were compared for the influence of postoperative pain control and wound healing rate.
Study NCT04485780 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: botulinum toxin type A
Description: In the outpatient department, patients who need hemorrhoidectomy were randomly assigned to two groups at a 1:1 ratio using a computer-generated list of random numbers (Microsoft Excel). One group received Botulinum toxin injection during the outpatient clinic one week before the operation(experimental group, EG), and the other group received injection during the operation(control group, CG). The two groups were compared for the influence of postoperative pain control and wound healing rate.
Study NCT01140607 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel (XRP6258)
Description: Pharmaceutical form:solution for infusion~Route of administration: intravenous
Study NCT01962064 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive assessment
Study NCT01962064 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brain imaging examination MRI
Study NCT00795132 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Busulfan
Description: This drug is a bifunctional alkylating agent. Busulfan is highly toxic to noncycling or slowly-cycling cells. Pharmacokinetic studies of the IV formulation in pediatrics have shown that using a dose of 0.8mg/kg IV q6 hours most patients will achieve AUC levels between 800 and 1300 uM/min, representing steady state levels between 600-900ug/ml. The manufacturer recommends higher doses, 1.1mg/kg for children less than 12kg. Because this is a reduced intensity study and infants on the study will be very heavily pretreated we will use the lower dose of 0.8mg/kg q6 hours for a total of 8 doses for all patients.
Study NCT02907125 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SEHER Intervention delivered by TSM
Description: SEHER Intervention The SEHER intervention will be delivered by a trained teacher, called as Teacher-as-SEHER Mitra (Mitra meaning friend) or lay health worker called as SEHER Mitra being trained to facilitate following activitiesAwareness generation activities for all stakeholders in school; Wall-magazine, Speak-out box, Competitions, School Health Promotion Committee, School health policies, Peer groups of students of class IX and X students, Workshops and talks for all the students from standard IX, and for teachers, and Counselling and referral services for all the students in the school.~This intervention will be delivered in each school over the academic year.
Study NCT02907125 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SEHER Intervention delivered by SM
Description: The SEHER intervention will be delivered by a lay health worker called as SEHER Mitra being trained to facilitate following activities: Awareness generation activities for all stakeholders in school; Wall-magazine, Speak-out box, Competitions, School Health Promotion Committee, School health policies, Peer groups of students of class IX and X students, Workshops and talks for all the students from standard IX, and for teachers, and Counselling and referral services for all the students in the school.~This intervention will be delivered in each school over the academic year.
Study NCT02907125 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Tarang AEP
Description: The comparison arm involves 'usual care' which in the study setting is the Tarang: Adolescence Education Programme comprising of 16 classroom sessions on process of growing-up, prevention of HIV/AIDS and other Sexually Transmitted Diseases (STDs), and prevention of substance and other drug abuse. This programme is delivered by a trained nodal teacher in the school over the academic year.
Study NCT02907125 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tarang AEP
Description: The comparison arm involves 'usual care' which in the study setting is the Tarang: Adolescence Education Programme comprising of 16 classroom sessions on process of growing-up, prevention of HIV/AIDS and other Sexually Transmitted Diseases (STDs), and prevention of substance and other drug abuse. This programme is delivered by a trained nodal teacher in the school over the academic year.
Study NCT00822887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vandetanib
Description: Dose level 1:100 mg qd Dose level 2:200 mg qd Dose level 3:300 mg qd
Study NCT00822887 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Fractionated Stereotactic Radiotherapy
Description: All patients will receive 36 Gy of radiation in three fractions, given in three consecutive days.
Study NCT01256996 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Air abrasion of the implant surface with a low abrasive powder
Description: Test treatment will be performed using the low abrasive powder in a standard air-polishing unit, which will be set up according to the manufacturer's instructions. The unit will be set to a medium water and powder setting, and the powder chamber will be filled to the indicated maximum powder level before treatment to ensure reproducible treatment conditions. The jet will be directed to the periodontal pocket for 5 s per surface (vestibular, lingual, mesio and distal) for subgingival plaque removal.
Study NCT02586324 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: global medium
Study NCT02586324 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SSM
Study NCT02924649 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early Intensive mobilisation
Description: The intervention will be performed using a tilt table with integrated stepping movements of the lower extremity (ERIGO, HOCOMA, Switzerland). The goal of the intervention session is that the patient stands upright for 20 minutes. If orthostatic intolerance or increase in intracranial pressure occurs the session will be paused. When the patient is stable mobilization is continued.
Study NCT02835157 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Balanced crystalloid solution
Description: Multiple electrolyte solution as boluses would be administered.
Study NCT02835157 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.9%sodium chloride
Description: saline as boluses would be administered
Study NCT00672217 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy for Insomnia (CBTI)
Description: Six 15-30 minute in-person or phone sessions that incorporate cognitive, behavioral and psycho-educational techniques focused on modifying the perpetuating factors that maintain insomnia.
Study NCT00672217 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Behavioral Placebo Treatment
Description: Six 15-30 minute in-person or phone sessions that begin with a review of the sleep diary, a general discussion of treatment progress and tabulation of sleep parameters.
Study NCT03911674 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral manual stimulation of feeding in preterm infants
Description: Manual stimulation of the cheeks (internal and external), lips, gums, tongue and palate by finger-strokin.
Study NCT02360007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interim Buprenorphine Treatment (IBT)
Description: The Interim Buprenorphine Treatment (IBT) includes:~1. Buprenorphine (BUP)~2. Computerized adherence monitoring (CAM): BUP will be dispensed via a portable device that makes each day's dose available only at a predetermined time.~3. Mobile health clinical support: An Interactive Voice Response (IVR) system to deliver clinical support~4. Urinalysis and adherence monitoring with participants contacted via IVR for random call-backs~5. HIV+Hepatitis Education delivered via iPad
Study NCT00046839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: celecoxib
Study NCT03258593 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CT
Description: Computed tomography (CT) at screening and every 12 months while on study.
Study NCT03258593 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI
Description: Magnetic resonance imaging (MRI) at screening and every 12 months while on study.
Study NCT02146989 — intervention group
Intervention type: OTHER
Intervention: reproducibility of upper extremity strength measurements
Description: inter-rater reliability and test-retest reliability
Study NCT01232972 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: vitrification of oocytes
Description: eggs will be preserved via vitrification the day they are retrieved from the participant
Study NCT01929044 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 654-II (anisodamine)
Description: 10mg injection
Study NCT01929044 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buscopan® (hyoscine butylbromide)
Description: 20mg injection